Publication Name	World Journal of Dermatology
Manuscript ID	21210
Country	France

Received	2015-07-02 09:23
Peer-Review Started	2015-07-06 08:31
To Make the First Decision	2015-07-27 15:56
Return for Revision	2015-07-31 14:56
Revised	2015-08-15 04:28
Second Decision	2015-11-09 10:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-11-25 16:30
Articles in Press	2015-11-25 16:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-01-16 19:35
Publish the Manuscript Online	2016-01-29 17:09

ISSN	2218-6190 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Dermatology
Manuscript Type	Systematic Reviews
Article Title	Clinical pharmacokinetics profile of ivermectin 1% cream after dermal applications on the face
Manuscript Source	Invited Manuscript
All Author List	Khaled Benkali, François Rony, Michael Graeber, Jean Jacovella, Jean-Paul Chappuis, Marie-Helene Peirone, Michel Poncet, Stéphane Delage, Ronan Bouer and Nathalie Wagner
Funding Agency and Grant Number
Corresponding Author	Khaled Benkali PhD, Galderma R and D, Les Templiers, 2400, route des Colles, 06410 Biot, France. khaled.behkali@galderma.com
Key Words	Ivermectin; Pharmacokinetic maximal usage trial; Metabolites; Plasma and rosacea
Core Tip	Papulopustular rosacea (PPR) is a chronic skin disease affecting patients face, with a dramatic impact on social and professional interactions. Ivermectin 1% cream is a new effective and safe treatment for PPR recently approved in many countries. This article presents the clinical pharmacokinetics (PK) assessments conducted during the drug development of Ivermectin 1% cream. Usually, for topical products, PK assessments are incomplete due to the low systemic exposure. For ivermectin cream, a comprehensive PK and metabolism program was conducted in healthy volunteers and PPR patients up to 1 year treatment. These provided valuable information to better assess ivermectin safety profile.
Publish Date	2016-01-29 17:09
Citation	Benkali K, Rony F, Graeber M, Jacovella J, Chappuis JP, Peirone MH, Poncet M, Delage S, Bouer R, Wagner N. Clinical pharmacokinetics profile of ivermectin 1% cream after dermal applications on the face. World J Dermatol 2016; 5(1): 57-64
URL	http://www.wjgnet.com/2218-6190/full/v5/i1/57.htm
DOI	http://dx.doi.org/10.5314/wjd.v5.i1.57

Full Article (PDF)	WJD-5-57.pdf
Full Article (Word)	WJD-5-57.doc
Manuscript File	21210-Review.docx
Answering Reviewers	21210-Answering reviewers.pdf
Audio Core Tip	21210-Audio core tip.wav
Biostatistics Review Certificate	21210-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	21210-Conflict-of-interest statement.pdf
Copyright License Agreement	21210-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	21210-Language certificate.pdf
Peer-review Report	21210-Peer-review(s).pdf
Scientific Misconduct Check	21210-Scientific misconduct check.pdf
Scientific Editor Work List	21210-Scientific editor work list.pdf